IBRX
Income statement / Annual
Last year (2023), ImmunityBio, Inc.'s total revenue was $622,000.00,
an increase of 159.17% from the previous year.
In 2023, ImmunityBio, Inc.'s net income was -$583.20 M.
See ImmunityBio, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$622,000.00 |
$240,000.00 |
$934,000.00 |
$605,000.00 |
$2.20 M |
$47,000.00 |
$45,000.00 |
$44,000.00 |
$236,000.00 |
$641,000.00 |
Cost of Revenue |
$0.00
|
$24.19 M
|
$0.00
|
$9.15 M
|
$9.01 M
|
-$3.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$622,000.00
|
-$23.95 M
|
$934,000.00
|
-$8.54 M
|
-$6.81 M
|
$3.16 M
|
$45,000.00
|
$44,000.00
|
$236,000.00
|
$641,000.00
|
Gross Profit Ratio |
1
|
-99.8
|
1
|
-14.12
|
-3.09
|
67.17
|
1
|
1
|
1
|
1
|
Research and Development Expenses |
$232.37 M
|
$248.15 M
|
$195.96 M
|
$139.51 M
|
$112.00 M
|
$53.42 M
|
$39.78 M
|
$26.55 M
|
$11.43 M
|
$1.60 M
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$28.39 M
|
$57.12 M
|
$95.39 M
|
$227.68 M
|
$4.33 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.07 M
|
-$3.30 M
|
-$1.00 M
|
-$1.47 M
|
$0.00
|
Selling, General & Administrative Expenses |
$129.62 M
|
$102.71 M
|
$135.26 M
|
$71.32 M
|
$46.46 M
|
$35.46 M
|
$53.82 M
|
$94.39 M
|
$226.21 M
|
$4.33 M
|
Other Expenses |
$886,000.00
|
-$736,000.00
|
$193,000.00
|
$1.49 M
|
-$534,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$362.87 M
|
$350.86 M
|
$331.21 M
|
$210.83 M
|
$158.45 M
|
$88.88 M
|
$93.60 M
|
$120.94 M
|
$237.64 M
|
$5.92 M
|
Cost And Expenses |
$362.87 M
|
$350.86 M
|
$331.21 M
|
$210.83 M
|
$158.45 M
|
$98.44 M
|
$99.17 M
|
$124.54 M
|
$239.11 M
|
$6.24 M
|
Interest Income |
$863,000.00
|
$2.71 M
|
$836,000.00
|
$1.73 M
|
$2.76 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$129.20 M
|
$63.52 M
|
$14.85 M
|
$9.07 M
|
$5.92 M
|
$433,000.00
|
$618,000.00
|
$66,000.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$18.51 M
|
$24.19 M
|
$19.12 M
|
$9.15 M
|
$9.01 M
|
$9.56 M
|
$5.57 M
|
$3.61 M
|
$1.47 M
|
$128,000.00
|
EBITDA |
-$436.18 M |
-$335.51 M |
-$315.38 M |
-$187.93 M |
-$142.27 M |
-$86.74 M |
-$90.73 M |
-$117.71 M |
-$235.71 M |
-$5.68 M |
EBITDA Ratio |
-701.26
|
-1433.24
|
-338.66
|
-322.53
|
-63.57
|
-1890.09
|
-2078.98
|
-2747.57
|
-1005.95
|
-9.49
|
Operating Income Ratio |
-582.4
|
-1463.74
|
-353.62
|
-365.09
|
-70.96
|
-2093.38
|
-2202.67
|
-2829.55
|
-1012.19
|
-9.69
|
Total Other Income/Expenses Net |
-$221.64 M
|
-$65.99 M
|
-$19.56 M
|
-$25.36 M
|
-$3.95 M
|
$1.66 M
|
$2.20 M
|
$3.12 M
|
$1.70 M
|
-$609,000.00
|
Income Before Tax |
-$583.89 M
|
-$417.29 M
|
-$349.84 M
|
-$226.03 M
|
-$160.26 M
|
-$96.73 M
|
-$96.92 M
|
-$121.38 M
|
-$237.18 M
|
-$6.21 M
|
Income Before Tax Ratio |
-938.73
|
-1738.69
|
-374.56
|
-373.61
|
-72.78
|
-2058.06
|
-2153.69
|
-2758.66
|
-1004.99
|
-9.69
|
Income Tax Expense |
-$40,000.00
|
$34,000.00
|
$9,000.00
|
-$1.85 M
|
-$105,000.00
|
-$503,000.00
|
-$493,000.00
|
-$572,000.00
|
-$301,000.00
|
$1,000.00
|
Net Income |
-$583.20 M
|
-$417.32 M
|
-$349.85 M
|
-$224.19 M
|
-$160.16 M
|
-$96.23 M
|
-$96.42 M
|
-$120.81 M
|
-$236.88 M
|
-$6.21 M
|
Net Income Ratio |
-937.61
|
-1738.83
|
-374.57
|
-370.56
|
-72.73
|
-2047.36
|
-2142.73
|
-2745.66
|
-1003.71
|
-9.69
|
EPS |
-1.15 |
-1.04 |
-0.9 |
-0.59 |
-0.42 |
-1.22 |
-1.2 |
-1.47 |
-3.31 |
-0.0197 |
EPS Diluted |
-1.15 |
-1.04 |
-0.9 |
-0.59 |
-0.42 |
-1.22 |
-1.2 |
-1.47 |
-3.31 |
-0.0197 |
Weighted Average Shares Out |
$508.64 M
|
$399.90 M
|
$389.23 M
|
$383.18 M
|
$383.18 M
|
$79.13 M
|
$80.58 M
|
$81.98 M
|
$71.52 M
|
$315.73 M
|
Weighted Average Shares Out Diluted |
$508.64 M
|
$399.90 M
|
$389.23 M
|
$383.18 M
|
$383.18 M
|
$79.13 M
|
$80.58 M
|
$81.98 M
|
$71.52 M
|
$315.73 M
|
Link |
|
|
|
|
|
|
|
|
|
|